Search clinical trials for: Durvalumab tremelimumab

Total 774 results

AstraZeneca

Recruiting

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)

Papillary Renal Cell Carcinoma

China, Czechia, Israel, Netherlands, Spain, United Kingdom, Korea, Republic of, Italy, India, Mexico, Turkey, Argentina, Australia, Canada, Germany, Russian Federation, Taiwan, United States, Poland, Brazil, Chile, Hong Kong, Ukraine, Franc... and more
European Organisation for Research and Treatment...

Withdrawn

Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)

Squamous Cell Head and Neck Carcinoma
New Mexico Cancer Care Alliance

Active, not recruiting

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States
Maximilian Diehn
AstraZeneca

Recruiting

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Non Small Cell Lung Cancer | NSCLC, Stage III | Nsclc

United States
Taofeek Owonikoko
AstraZeneca

Recruiting

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Extensive-stage Small-cell Lung Cancer

United States
Peking Union Medical College Hospital

Recruiting

A Real-world Study of Durvalumab for Lung Cancer in China

Non Small Cell Lung Cancer Stage III | Small-Cell Lung Cancer

China
AstraZeneca

Completed

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA)

Locally Advanced Cervical Cancer

United States, Taiwan, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Philippines, Poland, Russian Federation, China, Chile, South Africa
MedImmune LLC

Completed

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Head and Neck Cancer | Human Papilloma Virus

United States
The University of Hong Kong

Recruiting

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

Hong Kong
Mary Crowley Medical Research Center
AstraZeneca; Gradalis, Inc.

Completed

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Cervical Cancer | Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Carcinoma | Uterine Cancer

United States
GlaxoSmithKline
MedImmune LLC

Completed

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Neoplasms

United States, Canada, Australia
ARCAGY/ GINECO GROUP

Active, not recruiting

Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse (BOLD)

Epithelial Ovarian Cancer | Relapse

France
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Esophagus Adenocarcinoma

Germany
Stanford University
AstraZeneca

Recruiting

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

United States
Washington University School of Medicine
AstraZeneca; Gateway for Cancer Research

Recruiting

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

United States
AUSL Romagna Rimini
AstraZeneca; Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Recruiting

Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer (PANDORA)

RECTAL CANCER

Italy
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
Mary Feng, MD
AstraZeneca

Recruiting

Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition

Advanced Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Carcinoma in the Liver | Resectable Mass

United States
Northwestern University
National Cancer Institute (NCI); AstraZeneca; MedImmune LLC

Completed

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Malignant Glioma | Recurrent Glioblastoma

United States
Novartis Pharmaceuticals

Completed

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) (CONVERT)

Gastrointestinal Stromal Tumors

Brazil
Beijing Chest Hospital

Not yet recruiting

Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
Zhejiang Cancer Hospital

Not yet recruiting

Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung
Do-Youn Oh
AstraZeneca

Active, not recruiting

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

Korea, Republic of
hassan harby mohamed

Completed

Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules

Thyroid Nodule

Egypt
Masonic Cancer Center, University of Minnesota

Recruiting

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Lung Cancer | Adenocarcinoma of Lung

United States
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
Roswell Park Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma

United States
AstraZeneca
Daiichi Sankyo

Recruiting

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)

Advanced or Metastatic NSCLC

United States, Taiwan, Italy, Spain, Poland, Japan, Belgium, Turkey, France, Korea, Republic of
Celgene

Completed

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Canada, Spain, United Kingdom, United States, France, Austria, Germany, Italy, Netherlands, Belgium, Portugal, Poland
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States
Filipa Lynce, MD
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI)

Breast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer | Inflammatory Breast Cancer Stage III | HER2 Low Breast Adenocarcinoma

United States
Xin-Hua Xu

Completed

Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes

Non-small Cell Lung Cancer

China
MedImmune LLC

Completed

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Kidney Cancer | Clear Cell Renal Cell Carcinoma | Select Advanced Malignancies

United States, France, Canada, United Kingdom, Netherlands, Australia
Hospital Clinic of Barcelona

Completed

Randomized Diagnostic Trial Comparing Ethylglucuronide and Ethanol

Alcohol Use Disorder
Shanghai Cancer Hospital, China

Unknown

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT

China
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Stage IV Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Stage IVB Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Metastatic Malignant Female Reproductive System Neoplasm | Platinum-Resistant Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Not yet recruiting

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

Primary Central Nervous System Lymphoma (PCNSL)
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) (DUPLE)

Pulmonary Large-cell Neuroendocrine Carcinoma

Italy
AstraZeneca
Parexel

Recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

China, Netherlands, Korea, Republic of, Italy, Spain, Canada, Hungary, Japan, Argentina, France, United States, Taiwan, Poland, Serbia, United Kingdom, Hong Kong, Brazil, Germany, Belgium, Romania, India, Ireland, Australia
National Cancer Center Hospital East
AstraZeneca; Japan Agency for Medical Research and Development; Japan Clinical...

Not yet recruiting

Efficacy and Safety of CRT, Durvalumab and Surgery for SST (DEEP_OCEAN)

Non Small Cell Lung Cancer Stage III | Superior Sulcus Tumor | Non-small Cell Lung Cancer Stage IIB
Memorial Sloan Kettering Cancer Center

Terminated

A Study of Olaparib and Durvalumab in Prostate Cancer

Prostate Cancer

United States
MedImmune LLC

Completed

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Melanoma

Italy, United States, Canada, France
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair Deficiency

United States
AstraZeneca

Completed

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Melanoma

United States, Italy, Spain, Sweden, Belgium, Canada, Poland, Switzerland, France, Russian Federation, United Kingdom, Australia, Argentina, Germany, Netherlands, Israel, South Africa, Austria, Greece, Mexico, Slovakia
Asan Medical Center

Recruiting

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM)

Biliary Tract Cancer | DNA Damage Repair Deficiency

Korea, Republic of
National Cancer Institute (NCI)

Recruiting

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

EGFR-Mutated Non-Small-Cell Lung Carcinoma | Small Cell/Neuroendocrine

United States
University Health Network, Toronto

Completed

Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)

Microsatellite Stable Colorectal Carcinoma | Platinum Resistant Epithelial Ovarian Cancer Type II | Estrogen Receptor Positive and HER2 Negative Breast Cancer

Canada

Search clinical trials for: Durvalumab tremelimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations